Can Revlimid help with anemia in low-risk Myelodysplastic Syndromes?
Revlimid (lenalidomide) is a treatment option for anemia in low-risk myelodysplastic syndromes (MDS), but it is specifically approved for patients whose MDS cells have a deletion on chromosome 5 (del 5q). It is not for all low-risk MDS patients. For those with del 5q, Revlimid can reduce or eliminate the need for red blood cell transfusions.
What the research says
The FDA has approved Revlimid for transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q abnormality, with or without additional cytogenetic abnormalities 1. This approval is based on studies showing that lenalidomide can improve anemia and reduce transfusion dependence in this specific subgroup. For lower-risk MDS without del 5q, erythropoiesis-stimulating agents (ESAs) are the first-line treatment for anemia 67. If ESAs fail, options include lenalidomide (only for del 5q positive cases), hypomethylating agents, or clinical trials 8. A 2023 review notes that treatment goals for lower-risk MDS focus on improving anemia, quality of life, and possibly overall survival 6. It is important to note that Revlimid is not indicated for chronic lymphocytic leukemia outside of controlled trials 1, and its use in MDS is limited to the del 5q subtype.
What to ask your doctor
- Does my MDS have a deletion 5q abnormality? This determines if Revlimid is an option for me.
- What are the potential side effects of Revlimid, and how are they managed?
- If I do not have del 5q, what are the other treatments for my anemia, such as ESAs or clinical trials?
- How will my response to Revlimid be monitored, and what defines a successful response?
This question is drawn from common patient questions about Hematology and answered using cited medical research. We do not provide individualized advice.